Pharma: Page 10
-
Win McNamee via Getty Images
IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
By Amy Baxter • March 12, 2025 -
Getty Images
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
By Amy Baxter • March 11, 2025 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Getty Images
Pricing transparency is in the spotlight — and that could be good news for drugmakers
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
By Michael Gibney • March 11, 2025 -
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
By Meagan Parrish • March 10, 2025 -
Getty Images
As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges
Experts say cost and other barriers present challenges to returning to U.S. shores.
By Kelly Bilodeau • March 10, 2025 -
Getty Images
The time is ripe for pharma M&A. Why are drugmakers holding out?
The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.
By Michael Gibney • March 6, 2025 -
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025 -
Courtesy of AbbVie
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
By Jonathan Gardner • March 5, 2025 -
Getty Images
Americans want to participate in clinical trials — so why don’t they?
A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.
By Kelly Bilodeau • March 4, 2025 -
Courtesy of GSK Flickr page
How pharma CEO pay shifted for these 4 companies last year
Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.
By Amy Baxter • March 3, 2025 -
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
By Meagan Parrish • Feb. 28, 2025 -
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
By Michael Gibney • Feb. 27, 2025 -
Getty Images
Cancer vaccines have stumbled, but the approach is gaining new steam
The number of candidates in development has nearly doubled over the past 15 years.
By Kelly Bilodeau • Feb. 26, 2025 -
Getty Images
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
By Ned Pagliarulo • Feb. 25, 2025 -
Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
By Michael Gibney • Feb. 25, 2025 -
Chip Somodevilla via Getty Images
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
By Amy Baxter • Feb. 24, 2025 -
Sarah Silbiger via Getty Images
In FDA job cuts, experts see threat of far-reaching impact
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.
By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025 -
Getty Images
A look at Trump’s healthcare cuts — so far
How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.
By Meagan Parrish • Feb. 21, 2025 -
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
By Michael Gibney • Feb. 20, 2025 -
Drew Angerer via Getty Images
Challenges mount for vaccine makers
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.
By Amy Baxter • Feb. 19, 2025 -
Getty Images
Q&AMerck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.
By Alexandra Pecci • Feb. 19, 2025 -
Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
By Michael Gibney • Feb. 13, 2025 -
Getty Images
The kids are alright: How pharma can make inroads with Gen Z
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
By Amy Baxter • Feb. 12, 2025 -
Getty Images
In the crowded cardio space, it’s David vs. Goliath for small biotechs
What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.
By Alexandra Pecci • Feb. 11, 2025 -
Spencer Platt via Getty Images
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.
By Michael Gibney • Feb. 11, 2025
Previous
